Pfizer epilepsy drug Lyrica fails in phase III trial Medical Dialogues Bureau28 May 2019 9:00 AM ISTNew Delhi: Pfizer Inc. recently announced that a Phase 3 study to assess the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients 5...
Pfizer loses blockbuster Epilepsy drug patent fight in UK Supreme Court Medical Dialogues Bureau15 Nov 2018 11:42 AM ISTThe expiry of the basic patent on Lyrica five years ago had allowed generic drugmakers to launch cut-price versions of Pfizer's medicine, which...
FDA grants new indication for BRIVIACT for partial-onset seizures in patients 16 years and older with epilepsy. Ruby Khatun Khatun19 Sept 2017 9:24 AM ISTATLANTA and BRUSSELS: UCB announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for...
Eisai Pharma launches first-in-class epilepsy treatment Fycompa (Perampanel) in India Ruby Khatun Khatun24 Aug 2017 10:00 AM ISTEisai Pharmaceuticals India Pvt. Ltd, a leading Japanese pharmaceutical company announced the launch of Fycompa (perampanel), a new anti-epileptic...
